An Open Label, Uncontrolled, Study to Assess the Response of Peg-Intron [peginterferon alfa-2b] in naive Patients With Chronic Hepatitis B and D co-Infection.

Trial Profile

An Open Label, Uncontrolled, Study to Assess the Response of Peg-Intron [peginterferon alfa-2b] in naive Patients With Chronic Hepatitis B and D co-Infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Hepatitis B; Hepatitis D
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Dec 2008 Planned patient number (67) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top